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Abstract. The aim of the present study was to report on a 
complete synthetic approach, namely benzylation-hydro-
lysis-acylat ion-hydrogenation, to the synthesis of 
regioselectively acylated quercetin analogues using low-cost 
rutin as a starting material. Three quercetin analogues, quer-
cetin-3-O-propionate (Q-pr), quercetin-3-O-butyrate (Q-bu) 
and quercetin-3-O-valerate (Q-va), containing 3-, 4- and 
5-carbon aliphatic acyl chains, respectively, were synthesized 
and characterized with 1H nuclear magnetic resonance (NMR), 
13C NMR and mass spectrometry. Compared with quercetin, 
all three analogues exhibited improved lipophilicity. The 
lipophilicity of the analogue increased with increasing acyl 
chain length. Q-va exhibited the highest lipophilicity among 
the three analogues, but a lower water solubility compared 
with quercetin. By contrast, Q-pr and Q-bu exhibited 8.2- and 
4.7-fold higher water solubility compared with quercetin, 
respectively. The in vitro and in vivo studies demonstrated 
that Q-pr and Q-bu were more effective whereas Q-va was 
less effective in inhibiting platelet aggregation compared with 
quercetin. These results indicated that the water solubility and 
the lipophilicity of the analogues must be improved in order to 
achieve higher antiplatelet activity, and an optimal acyl chain 
length is crucial for the synthesized quercetin analogues to be 
more effective.
Introduction
Quercetin is the most abundant dietary flavonoid (1). It was 
previously demonstrated that quercetin exerts an antiplatelet 
effect that may be utilized to prevent and alleviate cardio-
vascular diseases (2-8). However, quercetin exhibits low 
hydrophilicity and low water solubility. In particular, the low 
water solubility is associated with the limited bioavailability 
of quercetin, and remains as a major obstacle to its therapeutic 
applications (9,10). The strong intermolecular packing of 
planar phenyl and hereto rings among quercetin molecules 
is presumably attributed to the low solubility of quercetin in 
water. Acylation of the hydroxyl groups of quercetin by an 
acyl donor containing a short aliphatic chain is a feasible way 
for destroying this intermolecular packing, hence improving 
the solvation of quercetin. However, non-selective acylation 
of hydroxyl groups may lead to loss of the biological activi-
ties of quercetin. The two adjacent hydroxyl groups at C3 and 
C4 in ring B, and the double bond between C2-C3 and the 
carbonyl group at C4 in ring C, are the most critical elements 
for quercetin to be biologically active (11,12). Therefore, to 
improve quercetin water solubility without compromising 
its biological activities, these functional groups must be kept 
intact.
Regioselective acylation of the hydroxyl group at C3 offers 
a reasonable solution (13,14). Chemo-enzymatic synthesis 
of regioselectively acylated quercetin has been previously 
investigated (13-17). However, synthesis methods without 
using enzymes are desirable, as they may reduce the reaction 
time and eliminate the need for costly enzymes. Only few 
studies using enzyme-free synthesis methods for the synthesis 
of quercetin analogues have been reported to date (18). A 
major challenge is that quercetin's hydroxyl groups may be 
randomly acylated, yielding a mixture of products. The aim 
of the present study was to develop a complete synthetic 
method (benzylation-hydrolysis-acylation-hydrogenation) for 
the synthesis of quercetin analogues using low-cost rutin as a 
starting material. With this method, regioselective acylation 
of C3 becomes possible as the hydroxyl of C3 is naturally 
protected with glycoside via a glycosidic bond. Three quercetin 
analogues were synthesized, quercetin-3-O-propionate (Q-pr), 
quercetin-3-O-butyrate (Q-bu) and quercetin-3-O-valerate 
(Q-va), with high yields (Fig. 1), and their water solubility, 
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lipophilicity and antiplatelet activity were examined against 
quercetin.
Materials and methods
Chemicals. Rutin (≥98%) was obtained from Nanjing TCM 
Institute of Chinese Materia Medica (Nanjing, China) and 
kept at 110˚C under 1.3 kPa for 12 h to remove bound water. 
Propionyl chloride, butyryl chloride and valeroyl chloride 
(analytical grade) were purchased from Aladdin Industrial 
Corporation (Shanghai, China). Benzyl bromide was obtained 
from Sinopharm Chemical Reagent (Shanghai, China) and 
distilled prior to use. N,N-dimethylformamide (DMF), trieth-
ylamine (TEA), and dichloromethane (DCM) were purchased 
form Tianjin Kemiou Chemical Reagent (Tianjin, China) and 
dehydrated prior to use. Adenosine diphosphate (ADP), arachi-
donic acid (AA) and platelet-activating factor (PAF) were 
purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, 
Germany). Palladium on carbon (Pd/C) (10%) was obtained 
from Sinopharm Chemical Reagent.
Animals. Male New Zealand rabbits (license no. 0017075) 
and male Wistar rats (250-300 g; license no. 0010061) were 
obtained from the Experimental Animal Center of Shandong 
Lukang Pharmaceutical (Jinan, China). The experimental 
procedures were approved by the Animal Experimentation 
Ethics Committee of Weifang Medical College and conducted 
in accordance with the guidelines of the National Health and 
Medical Research Council of China for the care and use of 
animals.
Synthesis of acylated quercetin analogues. The synthesis 
followed a complete chemical synthetic procedure, namely 
benzylation-hydrolysis-acylation-hydrogenation, using rutin 
as the starting material.
Step 1. Rutin (24.42 g, 40 mmol) and K2CO3 (18.35 g, 
133 mmol) were sequentially added to 160 ml of DMF 
under nitrogen and stirred for 1 h at room temperature (19). 
Subsequently, benzyl bromide (16 ml, 133 mmol) was added 
dropwise into the reaction mixture. The reaction mixture was 
stirred at 40˚C for 3 h under nitrogen, and then adjusted to pH 
6.0 with 10% (v/v) acetic acid in ice bath. Deionized water 
(300 ml) was then added to this mixture and the suspension 
was filtered.
Step 2. The filtered residue was dissolved in 600 ml of 
95% (v/v) ethanol at 70˚C. Hydrochloric acid [90 ml, 36% 
(w/w)] was added to the solution and the hydrolysis continued 
at 70˚C for 2 h. The suspension was cooled down to room 
temperature and then filtered to yield hydrolyzate. The 
hydrolyzate was washed with ice water until its pH became 
neutral.
Step 3. The hydrolyzate was dissolved in 250 ml of DCM 
followed by addition of chloride (propionyl chloride, butyryl 
chloride or valeroyl chloride) (44 mmol) and TEA (44 mmol). 
The mixture was stirred at room temperature until thin-layer 
chromatography (TLC) analysis showed the completeness of 
the reaction. The reaction mixture was then extracted with 
1 mol/l hydrochloric acid, and the organic layer was washed 
with a saturated aqueous solution of NaHCO3 and deion-
ized water. The pooled extracts were dried over Na2SO4 and 
then taken to dryness under vacuum to retrieve the acylated 
compound.
Step 4. The acylated compound was dissolved in 5,000 ml of 
ethanol/dioxane (1:1, v/v). Pd/C (2 g) was added to the solution. 
The reaction mixture was stirred at room temperature under 
hydrogen at atmospheric pressure for 2 h. Pd/C was filtered off, 
and the filtrate was evaporated in vacuum to retrieve the crude 
product of acylated quercetin analogues.
Purification of acylated quercetin analogues. Acylated 
derivatives were purified by using semi-preparative 
high-performance liquid chromatography (HPLC). An 
Agilent 1200 infinity preparative chromatography system 
performed chromatographic separation; this system was 
equipped with an Agilent Prep LC controller, an ultra-
violet (UV) detector (VWD-G1314B), a preparative column 
(ZORBAX-SB C18, 250x9.4 mm, 5 µm), an injector (3725i) 
and an auto-fraction collector (G1364C) (all from Agilent 
Technologies, Inc., Santa Clara, USA). Q-pr and Q-bu were 
purified using the linear elutions of acetonitrile/water (40:60, 
v/v and 30:70, v/v, respectively). Q‑va was purified using a 
linear gradient of acetonitrile and water for 0 min (30:70, v/v), 
7 min (40:60, v/v), 15 min (50:50, v/v), and 25 min (30:70, v/v). 
The flow rate was 5 ml/min, and the elution was performed at 
room temperature at 254 nm with the UV detector.
TLC. The acylation process was monitored using TLC on 
silica gel 60-GF254 (Merck KGaA), with a solvent mixture of 
ethyl acetate, methanol and acetic acid (at a ratio of 6:4:0.1, 
v/v/v). The plate was observed and detected under UV light 
(254 nm).
Nuclear magnetic resonance (NMR) spectroscopy and mass 
spectrometry (MS). Quercetin and three acylated derivatives, 
Q-pr, Q-bu and Q-va, were characterized with 1H NMR 
(500 MHz) and 13C NMR (100 MHz) in DMSO-d6 using a 
Bruker AV500 NMR spectrometer (Bruker Corporation, 
Billerica, MA, USA) with tetramethylsilane as an internal 
reference, and with MS without breaking into fragment 
ions using an Agilent 6410 liquid chromatography-mass 
spectrometer (Agilent Technologies, Inc.) with electrospray 
ionization.
Figure 1. Chemical structures of quercetin and the synthesized quercetin 
analogues. Q-pr, quercetin-3-O-propionate; Q-bu, quercetin-3-O-butyrate; 
Q-va, quercetin-3-O-valerate.
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Water solubility measurements. The water solubility of 
quercetin and the three acylated derivatives was determined 
according to the method described by Bonina et al (20). An 
excess amount of the compound was weighed into a glass 
tube containing 2 ml of water, and the tube was sealed with a 
Teflon‑lined cap. The mixture was stirred by a magnetic stirrer 
for 24 h at room temperature and was then filtered using a 
Millex HV13 filter unit (0.22 µm; Merck KGaA). The drug 
concentration in the saturated solution at 254 nm was deter-
mined using a Shimadzu chromatography system (LC-20AT), 
equipped with a UV detector (SPD-M10Avp) and a column 
(Shim-pack VP-ODS C18, 250x4.60 mm, 5 µm) (all from 
Shimadzu, Kyoto, Japan). The mobile phase was water/meth-
anol (70:30, v/v) at a flow rate of 1 ml/min.
Lipophilicity measurements. Lipophilicity may be estimated 
using reverse-phase chromatographic retention time due to the 
good association between the logarithm of the n-octanol/water 
partition coefficient (log P) and the logarithm of the capacity 
factor eluting with 100% water (log kw) determined using 
octadecyl silica columns. The value of log kw was obtained 
according to the method described by Braumann (21). Each 
compound was dissolved in methanol to a final concentration 
of 10 µg/ml. The sample (n=3) was filtered prior to injection 
using a filter (Millex HV13, 0.22 µm; Merck KGaA) and the 
aliquot (20 µl) was injected into the HPLC. The value of loga-
rithm of the capacity factor (log k') was calculated using the 
following equation:
where tr is the retention time of the flavonoid peak and t0 
denotes the retention time of the non-retained solvent peak. 
The HPLC condition was maintained the same as in the water 
solubility test. Only the volume fraction of methanol in mobile 
phase was changed for each measurement. A series of values 
of retention times and log k' were obtained. At a plot of log 
k' vs. the volume fraction of methanol in mobile phase, φ, 
extrapolated the data to 100% water to obtain the intersection 
point with the y axis, that is log kw value. A formula (21), which 
exhibited an excellent correlation between log kw and log P for 
the compound containing conjugated aromatic, was selected to 
calculated the value of log P:
log kw = 0.988 x log P + 0.020
The lipophilicity of quercetin and the three acylated 
derivatives was also calculated using the ACD/ChemSketch 
(Advanced Chemistry Development Inc., Toronto, Canada) 
and the Property Explorer Applet (www. openmolecules. org).
The association between log k' and φ, the values of log kw 
and log P of quercetin and the three acylated derivatives are 
presented in Table I.
In vitro antiplatelet activity test. Fresh whole blood was 
collected from healthy male New Zealand rabbits with 3.8% 
(w/v) sodium citrate at a volume ratio of 9:1. Platelet-rich 
plasma (PRP) was obtained by centrifugation at 328.7 x g for 
8 min at room temperature with no brake. PRP (300 µl) was 
incubated for 3 min at 37˚C in the presence of various final 
concentrations (0-350 µM) of quercetin or acylated analogue 
(n=8‑10), predissolved in DMSO. The final concentration of 
DMSO was <1.0% (v/v) to eliminate false positive results. 
Subsequently, platelet aggregation was stimulated by ADP 
(7 µM), AA (350 µM), or PAF (7.2 nM). The aggregation 
was monitored for 5 min using a platelet aggregometer 
(LBY-NJ4A, Precill, Beijing, China) with constant stirring 
at 241.5 x g, and the aggregation rates were recorded to 
determine the percentage of aggregation.
In vivo antiplatelet activity test. Administration of 
investigational agents and sample preparation for platelet 
aggregation were performed according to the method described 
by Mosawy et al (22). In brief, the rats (8-10 per group) were 
treated with 0.03 mmol/kg quercetin, Q-pr, Q-bu, Q-va, or 
control consisting of 0.5% DMSO with 2.2 mM polyethylene 
glycol (PEG) in saline. DMSO and PEG were used to improve 
the solubility of the investigational agents in the blood. The 
investigational agents were administered via a single intrave-
nous (IV) bolus via the tail vein. Experimental procedures and 
blood sample collection were performed 30 min after the IV 
bolus treatment. In each rat, 5 ml of fresh whole blood was 
collected into tubes containing 600 µl of 3.8% (w/v) sodium 
citrate via cardiac puncture. PRP was obtained by centrifuga-
tion at 377.3 x g for 8 min at room temperature with no brake. 
PRP was incubated for 3 min at 37˚C, and platelet aggregation 
was then stimulated by 7 µM ADP, 350 µM AA, or 7.2 nM 
PAF (final concentration). The aggregation was monitored 
for 5 min by using an aggregometer (LBY-NJ4A, Precill) at a 
constant stirring of 241.5 x g, and the aggregation rates were 
recorded to determine the percent of aggregation. The value 
of the aggregation inhibitory rate (AIR) was calculated as 
follows:
where A is the platelet aggregation rate of the sample and B is 
the platelet aggregation rate of the no compound treated group 
(control).
Statist ical analysis. All values are expressed as 
mean ± standard error of the mean. Comparisons between test 
samples and blank were performed using SPSS 9.0 software 
for Windows (SPSS Inc., Chicago, IL, USA) with Dunnett's 
test for post hoc comparisons, and P≤0.01 was considered to 
indicate statistically significant differences.
Results and Discussion
The synthesis of the three quercetin analogues involves 
four steps (Fig. 2). The hydroxyl group at C5 is considered 
non-reactive, as it forms an intramolecular hydrogen bond 
with the carbonyl at C4 (22). Therefore, this hydroxyl group 
remained intact throughout the reactions. In step 1, anhydrous 
K2CO3 was added to facilitate the formation of oxygen anions 
for hydroxyl groups at C3, C4 and C7 of rutin. Subsequently, 
benzyl bromide was added to benzylate the forming oxygen 
anions. A protic solvent, DMF, was used to avoid the produc-
tion of C-alkylated derivatives. The hydroxyl group at C3 
was recovered after hydrolysis of the glycoside (step 2), and 
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became the only reactive group for subsequent acylation in 
step 3. In the final step, the benzyl groups at C3, C4 and C7 
were removed by hydrogenation. The resulting acylated quer-
cetin derivatives were purified using semi‑preparative HPLC. 
All these derivatives were yellow powders.
The 1H NMR, 13C NMR and MS spectra collectively 
confirmed the structures of regioselectively acylated quercetin 
analogues.
Q‑pr. 1H NMR chemical shifts: δ (ppm) 12.23 (1H, s, 5-OH), 
10.67 (1H, br, s, 7-OH), 9.72 (3H, br s, 3, 3', 4'-OH), 7.33 (1H, d, 
H-2'), 7.27 (1H, d, H-6'), 6.92 (1H, d, H-5'), 6.48 (1H, d, H-8), 
6.25 (1H, d, H-6), 2.68 (2H, t, CH2), 1.15 (3H, t, CH3). 13C NMR 
chemical shifts: δ (ppm) 175.39 (C-4), 171.78 (C=O), 165.18 
(C-7), 161.54 (C-9), 157.08 (C-5), 156.36 (C-2), 149.78 (C-4'), 
145.95 (C-3'), 130.06 (C-3), 120.98 (C-1'), 120.08 (C-6'), 116.45 
(C-5'), 115.46 (C-2'), 103.89 (C-10), 99.55 (C-6), 94.56 (C-8), 
27.08 (CH2), 9.32 (CH3). MS (m/z) for Q‑pr: 381.1 [M+Na]+.
Q‑bu. 1H NMR chemical shifts: δ (ppm) 12.20 (1H, s, 
5-OH), 7.32 (1H, d, H-2'), 7.26 (1H, d, H-6'), 6.91 (1H, d, H-5'), 
6.47 (1H, d, H-8), 6.25 (1H, d, H-6), 2.63 (2H, t, CH2), 1.66 (2H, 
m, CH2), 0.96 (3H, t, CH3). 13C NMR chemical shifts: δ (ppm) 
174.95 (C-4), 170.48 (C=O), 164.72 (C-7), 161.08 (C-9), 156.63 
(C-5), 156.01 (C-2), 149.31 (C-4'), 145.45 (C-3'), 129.56 (C-3), 
120.54 (C-1'), 119.60 (C-6'), 115.95 (C-5'), 115.01 (C-2'), 103.55 
(C-10), 99.11 (C-6), 94.12 (C-8), 28.85 (CH2), 17.88 (CH2), 
13.33 (CH3). MS (m/z): 395.1 [M+Na]+.
Q‑va. 1H NMR chemical shifts: δ (ppm) 12.23 (1H, s, 
5-OH), 7.32 (1H, d, H-2'), 7.27 (1H, d, H-6'), 6.92 (1H, d, H-5'), 
6.48 (1H, d, H-8), 6.25 (1H, d, H-6), 2.65 (2H, t, CH2), 1.62 
(2H, m, CH2), 1.36 (2H, m, CH2), 0.90 (3H, m, CH3). 13C NMR 
chemical shifts: δ (ppm) 175.40 (C-4), 171.01 (C=O), 165.22 
(C-7), 161.55 (C-9), 157.09 (C-5), 156.48 (C-2), 149.77 (C-4'), 
145.97 (C-3'), 130.04 (C-3), 122.97 (C-1'), 120.07 (C-6'), 116.38 
(C-5'), 115.49 (C-2'), 103.89 (C-10), 99.56 (C-6), 94.56 (C-8), 
33.30 (CH2), 26.85 (CH2), 21.93 (CH2), 14.04 (CH3). MS (m/z): 
409.1 [M+Na]+.
In the 13C NMR spectrum of quercetin, the chemical shift 
of C3 appears at 136.18 ppm. However, the chemical shift of 
C3 in the synthesized analogues moved upfield (130.06 ppm 
for Q-pr, 129.56 ppm for Q-bu, and130.04 ppm for Q-va). 
Furthermore, the chemical shifts attributed to the ester 
carbonyl carbons of Q‑pr, Q‑bu and Q‑va were identified at 
171.78, 170.48 and 171.01 ppm, respectively. The ions at m/z 
381.1, m/z 395.1 and m/z 409.1 in the MS spectra correspond 
to sodiated adducts [M+Na]+ for Q-pr, Q-bu and Q-va, respec-
tively, consistent with the C3-substituted structures. This 
further confirmed the successful substitution of aliphatic acyls 
at C3.
Q‑pr and Q‑bu exhibited significantly improved water 
solubility (Table I). In particular, the water solubility of Q-pr 
was 8.2-fold higher compared with that of quercetin, while 
Q-bu exhibited a 4.7-fold higher water solubility. However, 
Q-va did not exhibit improved water solubility, as its water 
solubility was only 54% that of quercetin. These results 
suggested that the water solubility of quercetin analogues is 
affected by the carbon chain length at C3. Propionyl group 
has the shortest carbon chain, possessing a total of three 
carbons. It was shown to be the most effective in increasing 
water solubility. Butyryl group has one more methylene 
compared with propionyl group and a total of four carbons. 
It was still effective in increasing the water solubility of 
quercetin. However, the five‑carbon valeroyl group failed 
to render the quercetin analogue more water soluble. This 
was probably because 3- and 4-carbon short aliphatic acyl 
chains were efficient in disrupting intermolecular packing 
of quercetin molecules, thus enabling solvent molecules to 
enter the intermolecular gap to solvate quercetin molecules 
more easily. A further increase in chain length to 5 carbons 
made the hydrophobic effect dominant, making quercetin 
substituted with valeroyl group more hydrophobic. Their 
n‑octanol/water partition coefficients (Ps) were tested and 
three different methods were used to calculate log P (Table I). 
The lipophilicity of a compound is reflected by log P. Acyl 
chain length increase resulted in stronger lipophilicity. The 
results indicate that the log P values of the acylated deriva-
tives were higher than compared with of quercetin, and it 
increased with aliphatic acyl chain length with log P of Q-va 
being the highest.
Given that the acylation regioselectively occurred at C3 
of quercetin and the bioactive hydroxyl groups remained 
unchanged, the biological activities of quercetin were expected 
to be maintained. The in vitro assay demonstrated that the 
three acylated derivatives were able to inhibit platelet aggre-
gation induced by ADP, AA and PAF in a dose-dependent 
manner (Fig. 3). Q-pr and Q-bu were found to be more potent 
compared with quercetin.
Table I. Association between log k' and φ, and values of log kw, log P and water solubility of quercetin, Q-pr, Q-bu and Q-va.
   log Pb
 ----------------------------------------------
Compound log k'-φ (Ra) log kw A B C Water solubility (µg/ml)
Quercetin log k'=1.67–2.16φ (R=-0.98221) 1.67 1.67 2.07 1.49   1.98
Q-pr log k'=3.04–4.21φ (R=-0.9837) 3.04 3.06 2.77 2.43 16.27
Q-bu log k'=3.47–4.41φ (R=-0.9943) 3.47 3.48 3.30 2.88   9.36
Q-va log k'=3.72–4.77φ (R=-0.9995) 3.72 3.75 3.83 3.34   1.07
aLinear correlation coefficient. blog P was calculated as follows: A, according to the formula log kw=0.988–log POCT+ 0.020; B, using the 
ACD/ChemSketch; C, using the Property Explorer Applet (www.openmolecules.org). Q-pr, quercetin-3-O-propionate; Q-bu, quercetin-3-O-bu-
tyrate; Q-va, quercetin-3-O-valerate.
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Q-pr and Q-bu also displayed higher antiplatelet aggrega-
tion activities compared with quercetin in vivo (Fig. 4). In the 
ADP group, the AIRs of Q‑pr and Q‑bu were 67.8 and 52.7%, 
respectively, which were significantly higher compared with 
that of quercetin (43.5%). Although Q‑va successfully inhibited 
platelet aggregation to a certain extent with an AIR of 16.0%, 
it was significantly less potent compared with quercetin. The 
same order of drug activity of the four compounds was also 
observed in the AA and PAF groups.
In summary, regioselectively acylated quercetin analogues 
were successfully synthesized using a complete synthetic 
approach. The water solubility and lipophilicity of the resulting 
analogues were affected by the length of the aliphatic chains 
for acylation of the hydroxyl group located at C3 of quercetin. 
Aliphatic acyl donors containing three and four carbons were 
able to improve both the water solubility and the lipophilicity 
of the acylated analogues. As compared to quercetin, Q-pr and 
Q-bu exhibited a higher antiplatelet activity due to the higher 
water solubility and enhanced lipophilicity, whereas Q-va was 
less effective than quercetin due to its reduced water solubility, 
although its lipophilicity was the highest among the three 
analogues. Thus, an optimal acyl chain length is crucial for 
the quercetin analogues synthesized following this complete 
synthetic approach to be more effective.
Figure 4. In vivo antiplatelet aggregation activities of quercetin, Q-pr, Q-bu, and Q-va. *P≤0.01 vs. control. **P≤0.01 vs. quercetin. Q‑pr, quercetin‑3‑O-propionate; 
Q-bu, quercetin-3-O-butyrate; Q-va, quercetin-3-O-valerate; ADP, adenosine diphosphate; AA, arachidonic acid; PAF, platelet-activating factor.
Figure 3. In vitro antiplatelet aggregation activities of quercetin, Q-pr, Q-bu, and Q-va. Q-pr, quercetin-3-O-propionate; Q-bu, quercetin-3-O-butyrate; 
Q-va, quercetin-3-O-valerate; ADP, adenosine diphosphate; AA, arachidonic acid; PAF, platelet-activating factor.
Figure 2. Synthetic approach to the synthesis of regioselectively acylated quercetin analogues. Q-pr, quercetin-3-O-propionate; Q-bu, quercetin-3-O-butyrate; 
Q-va, quercetin-3-O-valerate; DMF, N,N-dimethylformamide; DCM, dichloromethane; Pd/C, palladium on carbon.
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